We're proud to share that the @US_FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: https://lnkd.in/etxeMZUK
Iovance Biotherapeutics, Inc.
Biotechnology Research
San Carlos, California 25,354 followers
Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.
About us
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
- Website
-
http://www.iovance.com/
External link for Iovance Biotherapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Carlos, California
- Type
- Public Company
- Founded
- 2007
- Specialties
- Immuno Oncology, Autologous Cell Therapy, Tumor Infiltrating Lymphocytes (TIL), Novel Cancer Immunotherapies, and cell therapy
Locations
Employees at Iovance Biotherapeutics, Inc.
Updates
-
Iovance Biotherapeutics, Inc. reposted this
Meet Robeal Russom in this latest video highlighting the impact of the Good Jobs Challenge. Robeal is a graduate of a 2024 partnership between ourselves, The Wistar Institute, and Navy Yard Philadelphia for roles with Iovance Biotherapeutics, Inc. This video is part of a series produced by Philadelphia Works, Inc.
Alumni Spotlight-Robeal-Aseptic Manufacturing Technician
https://www.youtube.com/
-
This #LungCancerAwarenessMonth, we honor those afflicted by non-small cell lung cancer (#NSCLC), one of the most prevalent cancers, and their caregivers. Iovance is committed to investigating potential new therapies for advanced NSCLC, learn more: https://lnkd.in/gwBdYmFG. #LCAM2024
-
-
Dr. Raj Puri has been promoted to Chief Regulatory Officer at Iovance! Raj has been instrumental in our U.S. FDA approval and in advancing regulatory submissions in the EU, UK, Canada, Australia, and Switzerland. Raj has also played a crucial role in advancing our product pipeline. Congratulations Raj! https://lnkd.in/eSJCJFRM
-
-
Today, our COO Igor Bilinsky and SVP Medical Affairs Peter A. Prieto, MD, MPH, CMQ, FACS, FSSO will participate in a fireside chat at the Stifel 2024 Healthcare Conference. Register here for the live webcast or replay: https://lnkd.in/e3gnPPdA
-
-
Applications are now open for our next Skills Initiative cohort!
Now accepting applications for the next cohort of the Skills Initiative at the Navy Yard! Are you a Philadelphia resident looking to break into the life-sciences sector? Our workforce development program will provide you with training and help connect you with open roles at the Navy Yard-based company Iovance Biotherapeutics, Inc. You'll get paid to train! Learn more below. Deadline to apply is November 22, 2024, by 5 p.m.
Applications now open for Skills Initiative at the Navy Yard! - Navy Yard
https://navyyard.org
-
Iovance Biotherapeutics, Inc. reposted this
A new immunotherapy combination studied at Moffitt shows adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients. https://lnkd.in/e28mcEkj
-
-
Updated preliminary results from Cohort 3A in the IOV-COM-202 trial are being presented in a late breaking poster at #SITC2024: https://lnkd.in/e9CHwX_m
Ben Creelan, MD presents updated results from a multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC. #SITC24 #MoffittSITC24 Society for Immunotherapy of Cancer (SITC) #LateBreakingAbstract
-
Today we announced our third quarter and year-to-date 2024 financial results and corporate updates: https://lnkd.in/ebJp8mwJ We will host a live audio webcast at 4:30 pm ET, please register here for the live webcast or replay: https://lnkd.in/efprW2Yi
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 | IOVANCE Biotherapeutics, Inc.
ir.iovance.com